Hassan I. Ahmed - Alembic Global Advisors LLC
Analyst · Alembic Global
Understood, understood. Now, as a follow-up, I guess, a two-part follow-up. It just seems that 2017 obviously is a bit of a transitional year for you guys, heavy turnaround schedule, sprucing up some of the sort of acquired assets and the like. So the first part of the question is that as we look at 2018, is it fair to assume that the bulk of your turnarounds are behind you? So that's part one. Then part two is, if that truly is the case, it just seems that the underlying earnings power thus far has been masked by all of these turnarounds. So, as I sit there, take a look at your Q2 numbers, call it around $420 million in recurring EBITDA, adjusting for the sort of Axiall deal-related cost and the like, and then on top of that, one can add around $60 million, call it, $64 million, as you said, in terms of lost EBITDA because of the turnaround. So, very simplistically, if I just annualize those numbers, I mean, I come up with an earnings power of north of $1.9 billion, and that's not even fully factoring in the full impact of the Axiall synergies. So, I mean, barring the complete meltdown, I mean, it seems chlor-alkali fundamentals are fine and improving, so barring the complete meltdown in Olefins, I mean, isn't that the right way we should think about sort of the go-forward earnings power of the company post Olefins turnarounds?